JAK2 and myeloproliferative neoplasm: Additionally, JAK2 mutations and activation of the JAK–STAT pathway are implicated in the chronic inflammatory state associated with MPN progression, development of second lymphoid and solid malignancies, and increased cardiovascular disease risk.2, 3